Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 antibody therapy for epithelial skin malignancies (NMSC-PD1 Study)
jRCT2031190048Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in cutaneous squamous cell carcinoma (cSCC), extramammary Paget disease (EMPD) and cutaneous malignancy, sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (central review, RECIST 1.1). Started Sep 2019; status: active, not recruiting.
02
Conditions
cutaneous squamous cell carcinoma (cSCC)extramammary Paget disease (EMPD)cutaneous malignancy
Beyond the preview
Go deeper on jRCT2031190048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031190048.